Found: 6
Select item for more details and to access through your institution.
Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects.
- Published in:
- Journal of Clinical Pharmacology, 2014, v. 54, n. 9, p. 968, doi. 10.1002/jcph.286
- By:
- Publication type:
- Article
Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers.
- Published in:
- British Journal of Clinical Pharmacology, 2004, v. 57, n. 5, p. 652, doi. 10.1111/j.1365-2125.2004.02068.x
- By:
- Publication type:
- Article
The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans.
- Published in:
- Journal of Neuroscience, 2015, v. 35, n. 3, p. 1199, doi. 10.1523/JNEUROSCI.4129-14.2015
- By:
- Publication type:
- Article
Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor.
- Published in:
- Journal of Neuroscience, 2011, v. 31, n. 46, p. 16507, doi. 10.1523/JNEUROSCI.3647-11.2011
- By:
- Publication type:
- Article
Determining Pharmacological Selectivity of the Kappa Opioid Receptor Antagonist LY2456302 Using Pupillometry as a Translational Biomarker in Rat and Human.
- Published in:
- International Journal of Neuropsychopharmacology, 2015, v. 18, n. 2, p. 1, doi. 10.1093/ijnp/pyu036
- By:
- Publication type:
- Article
Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2003, v. 73, n. 3, p. 170, doi. 10.1067/mcp.2003.28
- By:
- Publication type:
- Article